MedPath

Prednisone

Generic Name
Prednisone
Brand Names
Deltasone, Rayos, Winpred
Drug Type
Small Molecule
Chemical Formula
C21H26O5
CAS Number
53-03-2
Unique Ingredient Identifier
VB0R961HZT
Background

A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication

Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions
Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
Associated Therapies
Palliative Treatment

Treatment With Prednisone of Women With RPL or RIF Positive to Antithyroid Antibodies and Embryotoxicity Test

Phase 4
Completed
Conditions
Recurrent Pregnancy Loss, Not Pregnant
Recurrent Implantation Failure
Interventions
First Posted Date
2024-10-15
Last Posted Date
2024-10-16
Lead Sponsor
Centre for Endocrinology and Reproductive Medicine, Italy
Target Recruit Count
42
Registration Number
NCT06641440
Locations
🇮🇹

CERM-Hungaria IVF Center, Rome, RM, Italy

🇮🇹

Cerm-Hungaria, Rome, Italy

REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE)

Phase 3
Not yet recruiting
Conditions
Nephrotic Syndrome in Children
Nephrotic Syndrome, Minimal Change
Nephrotic Syndrome
Nephrotic Syndrome,idiopathic
Interventions
First Posted Date
2024-10-10
Last Posted Date
2024-10-10
Lead Sponsor
The Hospital for Sick Children
Target Recruit Count
50
Registration Number
NCT06635720
Locations
🇨🇦

The Hospital for Sick Children, Toronto, Ontario, Canada

A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)

Phase 1
Recruiting
Conditions
Healthy
Interventions
First Posted Date
2024-10-09
Last Posted Date
2024-11-15
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
14
Registration Number
NCT06633419
Locations
🇺🇸

Celerion ( Site 0001), Tempe, Arizona, United States

A Randomized, Placebo-controlled Trial of Prednisone in Refractory Restless Legs Syndrome: a Pilot Study

Phase 1
Not yet recruiting
Conditions
Restless Legs Syndrome
Interventions
Drug: Placebo
Drug: Prednisone
First Posted Date
2024-10-08
Last Posted Date
2024-10-08
Lead Sponsor
Scripps Health
Target Recruit Count
50
Registration Number
NCT06631300

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

Phase 2
Not yet recruiting
Conditions
Peripheral T Cell Lymphoma
Interventions
First Posted Date
2024-10-08
Last Posted Date
2024-10-08
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT06630091
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

Phase 3
Not yet recruiting
Conditions
Pyoderma Gangrenosum
Interventions
Drug: Placebo matching to spesolimab
Drug: Spesolimab
Drug: Prednisone
Drug: Prednisolone
First Posted Date
2024-10-03
Last Posted Date
2024-12-24
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
90
Registration Number
NCT06624670
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Medical Dermatology Specialists Phoenix, Phoenix, Arizona, United States

🇺🇸

University of California Irvine, Orange, California, United States

and more 82 locations

The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy

Phase 2
Not yet recruiting
Conditions
Primary Membranous Nephropathy
Interventions
First Posted Date
2024-09-26
Last Posted Date
2024-09-26
Lead Sponsor
Renmin Hospital of Wuhan University
Target Recruit Count
172
Registration Number
NCT06614985
Locations
🇨🇳

Renmin Hospital of Wuhan university, Wuhan, Hubei China, China

Systemic Oral Glucocorticoids for the Treatment of Acute Osteoarthritis Pain in the Emergency Department

Phase 4
Not yet recruiting
Conditions
Osteoarthritis
Osteoarthritis (OA) of the Knee
Osteoarthritis (OA) of the Shoulder
Osteoarthritis (OA) of the Hip
Interventions
First Posted Date
2024-09-19
Last Posted Date
2024-09-19
Lead Sponsor
WellSpan Health
Target Recruit Count
192
Registration Number
NCT06603662
Locations
🇺🇸

WellSpan York Hospital, York, Pennsylvania, United States

A Multicenter, Randomized, Controlled Trial of Prednisone Combined with Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis with Moderate to Severe Interface Hepatitis Characteristics

Phase 2
Conditions
Primary Biliary Cholangitis (PBC)
Interventions
First Posted Date
2024-09-19
Last Posted Date
2024-12-27
Lead Sponsor
Han Ying
Target Recruit Count
244
Registration Number
NCT06591468
Locations
🇨🇳

Xijing hospital, Xi'an, Shaanxi, China

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Phase 2
Not yet recruiting
Conditions
Diffuse Large B Cell Lymphoma (DLBCL)
Interventions
First Posted Date
2024-09-13
Last Posted Date
2024-09-19
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
31
Registration Number
NCT06594939
Locations
🇺🇸

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath